Company research
INCYTE CORP
CIK 879169Updated Sep 24, 2026
SecurityINCY · NASDAQ · equity
Name history
INCYTE INC · through Mar 28, 2003INCYTE GENOMICS INC · through Feb 25, 2003INCYTE PHARMACEUTICALS INC · through Apr 18, 2000
INCY price & chart
Loading TradingView…
NASDAQ:INCY on TradingView ↗About the company
Incyte is redefining what’s possible in biopharmaceutical innovation. Through deep scientific expertise and a relentless focus on patients, we have built an established portfolio of first-in-class medicines and an extensive portfolio of next-generation medicines across our key franchises: Hematology, Oncology and Inflammation and Autoimmunity. To learn more, visit Incyte.com and Investor. Incyte.com. Follow us on social media: LinkedIn, X and Instagram.
In the news
Recent filings
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 6,957,973,000Source | 5,444,322,000Source | 6,782,107,000Source | 5,840,984,000Source |
| Property, Plant and Equipment, NetUSD | 730,885,000Source | 763,411,000Source | 751,513,000Source | 739,310,000Source |
| GoodwillUSD | 133,000,000Source | 155,593,000Source | 155,593,000Source | 155,593,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 3,097,817,000Source | 1,687,829,000Source | 3,213,376,000Source | 2,951,422,000Source |
| Accounts Receivable | — | — | — | — |
| Inventory, NetUSD | 101,060,000Source | 58,872,000Source | 62,972,000Source | 41,995,000Source |
| Assets, CurrentUSD | 5,023,902,000Source | 3,239,030,000Source | 4,645,402,000Source | 4,092,850,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 317,831,000Source | 168,912,000Source | 182,830,000Source | 167,011,000Source |
| Other Assets, NoncurrentUSD | 18,166,000Source | 10,848,000Source | 52,107,000Source | 25,435,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 1,790,495,000Source | 1,996,694,000Source | 1,592,270,000Source | 1,470,865,000Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 198,000Source | 193,000Source | 224,000Source | 223,000Source |
| Retained Earnings (Accumulated Deficit)USD | 213,769,000Source | -1,072,881,000Source | 160,385,000Source | -437,214,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 25,462,000Source | -13,121,000Source | 13,106,000Source | 15,069,000Source |
| Stockholders' Equity Attributable to ParentUSD | 5,167,478,000Source | 3,447,628,000Source | 5,189,837,000Source | 4,370,119,000Source |
| Additional Paid in Capital, Common StockUSD | 4,928,049,000Source | 4,533,437,000Source | 5,016,122,000Source | 4,792,041,000Source |
| Liabilities and EquityUSD | 6,957,973,000Source | 5,444,322,000Source | 6,782,107,000Source | 5,840,984,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 1,515,170,000Source | 1,641,847,000Source | 1,240,379,000Source | 1,157,077,000Source |
| Operating Lease, Liability, CurrentUSD | 5,697,000Source | 5,583,000Source | 5,686,000Source | 8,195,000Source |
| Accounts Payable, CurrentUSD | 209,938,000Source | 197,465,000Source | 109,601,000Source | 277,546,000Source |
| Operating Lease, Liability, NoncurrentUSD | 14,508,000Source | 16,793,000Source | 14,284,000Source | 14,109,000Source |
| Other Liabilities, NoncurrentUSD | 165,270,000Source | 167,543,000Source | 149,151,000Source | 99,243,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 1,031,501,000Source | 1,212,048,000Source | 935,569,000Source | 701,053,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | 1,286,650,000Source | 32,615,000Source | 597,599,000Source | 340,660,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 93,286,000Source | 89,248,000Source | 82,660,000Source | 67,855,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 249,346,000Source | 266,058,000Source | 215,889,000Source | 188,420,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | 170,772,000Source | 111,586,000Source | 98,678,000Source | 28,579,000Source |
| Increase (Decrease) in InventoriesUSD | 58,513,000Source | 127,633,000Source | 170,151,000Source | 67,504,000Source |
| Increase (Decrease) in Accounts PayableUSD | 6,562,000Source | 88,159,000Source | -167,945,000Source | 105,436,000Source |
| Deferred Income Tax Expense (Benefit)USD | 247,685,000Source | -85,553,000Source | -158,898,000Source | 57,091,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | 1,413,498,000Source | 335,337,000Source | 496,487,000Source | 969,941,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -102,610,000Source | 157,517,000Source | -207,677,000Source | -78,542,000Source |
| Cash flows from financing activities: | ||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | 76,818,000Source | 40,302,000Source | 28,550,000Source | 26,301,000Source |
| Payments for Repurchase of Common StockUSD | 0Source | 2,004,790,000Source | — | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 101,039,000Source | -2,021,547,000Source | -20,033,000Source | -794,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 1,410,218,000Source | -1,525,770,000Source | 262,101,000Source | 893,960,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 3,099,669,000Source | 1,689,451,000Source | 3,215,221,000Source | 2,953,120,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Income Taxes Paid, NetUSD | 212,178,000Source | 373,056,000Source | 378,206,000Source | 136,242,000Source |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | -1,709,000Source | 2,923,000Source | -6,676,000Source | 3,355,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 249,300,000Source | 266,100,000Source | 215,900,000Source | 188,400,000Source |
| Amortization of Intangible AssetsUSD | 26,700,000Source | 23,600,000Source | 22,500,000Source | 21,500,000Source |
| DepreciationUSD | 66,600,000Source | 65,600,000Source | 60,100,000Source | 46,300,000Source |
| Equity Securities, FV-NI, Gain (Loss)USD | 21,310,000Source | 116,025,000Source | — | — |
| Equity Securities, FV-NI, Unrealized Gain (Loss)USD | — | — | 43,893,000Source | -87,590,000Source |
| Gain (Loss) Related to Litigation SettlementUSD | 242,251,000Source | — | — | — |
| GoodwillUSD | 133,000,000Source | 155,593,000Source | 155,593,000Source | 155,593,000Source |
| Income Tax Expense (Benefit)USD | 377,801,000Source | 284,015,000Source | 236,616,000Source | 188,456,000Source |
| InterestExpenseNonoperatingUSD | 2,428,000Source | 2,280,000Source | — | — |
| Investment Income, InterestUSD | 105,600,000Source | 128,710,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | 1,286,650,000Source | 32,615,000Source | 597,599,000Source | 340,660,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | 1,286,650,000Source | 32,615,000Source | 597,599,000Source | 340,660,000Source |
| Other Nonoperating Income (Expense)USD | 25,110,000Source | 12,809,000Source | 172,348,000Source | 39,932,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 5,141,242,000Source | 4,241,217,000Source | 3,695,649,000Source | 3,394,635,000Source |
| Cost of Goods and Services Sold | — | — | — | — |
| Gross Profit (Calculated) · Derived | — | — | — | — |
| Selling, General and Administrative ExpenseUSD | 1,376,206,000Source | 1,242,157,000Source | 1,161,293,000Source | 1,002,140,000Source |
| Operating Income (Loss)USD | 1,514,859,000Source | 61,366,000Source | 620,525,000Source | 579,440,000Source |
| Other Nonoperating Income (Expense)USD | 25,110,000Source | 12,809,000Source | 172,348,000Source | 39,932,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | 1,664,451,000Source | 316,630,000Source | 834,215,000Source | 529,116,000Source |
| Income Tax Expense (Benefit)USD | 377,801,000Source | 284,015,000Source | 236,616,000Source | 188,456,000Source |
| Net Income (Loss) Attributable to ParentUSD | 1,286,650,000Source | 32,615,000Source | 597,599,000Source | 340,660,000Source |
| Earnings Per Share, BasicUSD per share | 6.59Source | 0.16Source | 2.67Source | 1.53Source |
| Earnings Per Share, DilutedUSD per share | 6.41Source | 0.15Source | 2.65Source | 1.52Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 195,204,000Source | 207,110,000Source | 223,628,000Source | 222,004,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 200,700,000Source | 210,530,000Source | 225,928,000Source | 223,958,000Source |
| Interest Expense (non-operating)USD | 2,428,000Source | 2,280,000Source | — | — |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 26,700,000Source | 23,600,000Source | 22,500,000Source | 21,500,000Source |
| Costs and ExpensesUSD | 3,626,383,000Source | 4,179,851,000Source | 3,075,124,000Source | 2,815,195,000Source |
| Current Income Tax Expense (Benefit)USD | 130,116,000Source | 369,568,000Source | 395,514,000Source | 131,365,000Source |
| Gain (Loss) Related to Litigation SettlementUSD | 242,251,000Source | — | — | — |
| Interest ExpenseUSD | — | — | 2,551,000Source | 2,666,000Source |
| Investment Income, InterestUSD | 105,600,000Source | 128,710,000Source | — | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | 1,286,650,000Source | 32,615,000Source | 597,599,000Source | 340,660,000Source |
| Research and Development ExpenseUSD | 2,050,152,000Source | 2,606,848,000Source | 1,627,594,000Source | 1,585,936,000Source |
Filing attachments
march2026titlechanges-ex991.htm · 8-K · 2026-03-26
EX-99.1 2 march2026titlechanges-ex991.htm EX-99.1 Document Exhibit 99.1 FOR IMMEDIATE RELEASE Incyte Announces Executive Leadership Appointments WILMINGTON, Del. - March 25, 2026 - Incyte (NASDAQ:INCY) today announced appointments among its executive leadership team to support the Company’s strategic focus and long-term growth plans. Pablo J. Cagnoni, M.D., has been appointed President, Incyte and Global Head of Research and Development. In this role, Dr. Cagnoni will retain responsibil…
Read attachment ↗